VIVOS THERAP. DL-,0001

On August 31, Vivos Therapeutics entered into twelve exchange agreements with Streeterville Capital and converted outstanding principal claims of $2,861,270 into 11,445,080 common shares at $0.25 each. On August 4 the company had already converted other claims into preferred and common shares; the outstanding balance of the Streeterville note stood at about $3.7 million (including fees and discount) as of August 31. The conversions are intended to reduce liabilities and increase shareholders’ equity; final amounts will be reported in the respective quarterly filing. » More on de.investing.com

Vivos Therapeutics has reached final agreements with South Palm Cardiovascular Associates to establish a physician-led sleep and airway medicine center in Palm Beach County and plans to hold a majority stake of about 75% through the joint venture AIM Florida LLC. The partners are evaluating locations and lease agreements; patient operations are expected to begin in Q1 2027. An initial "Sleep Optimization Team" for about 250 patients per month is planned; Vivos estimates annual revenue potential of up to $6 million with contribution margins of at least 30%. South Palm is contributing a cardiology practice with roughly 30,000 patients; the offering will include integrated diagnostics and treatments for sleep apnea and cardiovascular patients. » More on de.investing.com

Vivos Therapeutics announces the opening of a diagnostic and treatment center in Henderson, Nevada, on August 27. The facility is expected to more than double annual output in Henderson to over $10 million and, at full capacity, employ up to 30 staff. Offered services will include diagnostic testing, clinical evaluations and treatments such as FDA-cleared oral appliances, dental sleep medicine, laser and myofunctional therapy. Vivos expects immediate revenue impact in the Las Vegas market due to increased referrals since May/June. » More on de.investing.com